Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279457 · ClinicalTrials.gov registry record · Phase 4
Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System
A Phase 4 study, sponsored by CAMC Health System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,802
- Enrollment target
NCT04279457: Recruiting Phase 4 study, sponsored by CAMC Health System.
NCT04279457 is a Phase 4 study that is actively recruiting participants, run by CAMC Health System. The registered enrollment target is 1,802 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (248% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04279457, a Phase 4 study, is actively recruiting participants, sponsored by CAMC Health System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,802 participants
- Enrollment target
Study Summary
Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures which require the use of intravenous contrast media. The reported incidence of contrast induced nephropathy (CIN) in high-risk patients following CAG varies from 10% to 30%. The high rate of CIN in post-PCI patients could be related either to the patient (advanced age, previous CKD, diabetes, dehydration, and concomitant use of other nephrotoxic drugs) or procedure related (intra-arterial route of administration, use of high osmolar contrast media, repeated exposure to contrast within 48 hours, volume of contrast used). Several strategies to prevent or treat CIN have been developed, including hydration, N-acetyl-cysteine, statins, ascorbic acid, bicarbonate, aminophylline, forced diuresis, renal replacement therapy, and choice of low-osmolarity or alternative agents, but one of the most obvious means is to minimize contrast volume. The DyeVert plus Contrast Reduction System, is designed to lower the amount of contrast dye the kidneys are exposed to during a procedure. Because the amount of contrast dye is precisely controlled. The purpose of this prospective study is to understand how the monitoring system of Dye-Vert Plus will impact Acute Kidney Injuries rates in high-risk patients undergoing cardiac catheterization when used in conjunction with a standardized hydration policy.
Primary Outcome
Determined by GFR levels
Interventions
- DEVICE DyeVert Plus System
- OTHER Standardized hydration protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,802 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2022-02-03 |
| Phase | Phase 4 |
What NCT04279457 shows while recruiting
NCT04279457 is an interventional study that assigns participants to a tested intervention. Its 1,802 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (248% higher).
The record links to 0 conditions, and to 2 interventions - of which DyeVert Plus System is the first listed.
NCT04279457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04279457 about?
NCT04279457 is a clinical study titled "Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System". Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures which require the use of intravenous contrast media. The reported incidence of contrast induced nephropathy (CIN) in high-risk patients following CAG var...
What is the current status of trial NCT04279457?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,802 participants. The study started on 2020-02-03. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT04279457?
The interventions under investigation include: DyeVert Plus System (DEVICE), Standardized hydration protocol (OTHER).
Who is sponsoring clinical trial NCT04279457?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04279457's enrollment target sits among peer trials
1,802 45th of 2000 higher than 1,956 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI